ATryn Antithrombin (Recombinant)
ATryn® Antithrombin (Recombinant) is the first and only plasma-free antithrombin concentrate. ATryn also holds the distinction of being the first product developed using rPRO Technology — a more natural, scalable and cost-effective method of protein production.
ATryn received FDA approval in 2009, and marketing authorization by the European Commission prior to that in 2006.
Comprehensive Distributor Network
ATryn is available through the following distributors, who should be contacted directly for product ordering.
7930 Arjons Drive, Suite A
San Diego, CA 92126
3101 Gaylord Parkway, Third Floor
Frisco, TX 75034
120 Research Drive
Columbia, SC 29203
4405 East Cotton Center Blvd.,
Phoenix, AZ 85040
Cardinal Health SPD
305 Tech Park Drive, Suite 113
La Vergne, TN 37086
FFF Enterprises, Inc.
41093 County Center Drive
Temecula, CA 92591
McKesson Plasma and BioLogics, LLC
401 Mason Road
La Vergne, TN 37086
National Hospital Specialties (NHS)
65 Commerce Way
Hackensack, NJ 07601
Indications and Usage
ATryn is a recombinant antithrombin indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.
Important Safety Information
ATryn is contraindicated in patients with known hypersensitivity to goat and goat milk proteins. Allergic-type hypersensitivity reactions, including anaphylaxis, are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur during administration, treatment must be discontinued immediately and emergency treatment should be administered.
The anticoagulant effect of drugs that use antithrombin to exert their anticoagulation may be altered when ATryn is added or withdrawn. To avoid excessive or insufficient anticoagulation, coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) are to be performed regularly, at close intervals, and in particular in the first hours following the start or withdrawal of ATryn. Additionally, patients should be monitored for the occurrence of bleeding or thrombosis in such situations. The serious adverse reaction that has been reported in clinical studies is hemorrhage (intra-abdominal, hemarthrosis, and post procedural). The most common adverse events reported in clinical trials at a frequency of ≥5% are hemorrhage and infusion site reaction. For more information, please see full Prescribing Information, visit www.atryn.com, or call 800-610-3776.